Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Acceptability of Long-Acting Cabotegravir for HIV Prevention in Adolescent Females (HPTN 084-01)
NCT04824131Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2020; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04824131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824131.